TY - JOUR
T1 - Effect of carbamazepine and oxcarbazepine on wild-type and mutant neuronal nicotinic acetylcholine receptors linked to nocturnal frontal lobe epilepsy
AU - Di Resta, Chiara
AU - Ambrosi, Paola
AU - Curia, Giulia
AU - Becchetti, Andrea
PY - 2010/9
Y1 - 2010/9
N2 - Carbamazepine (5H-dibenz[b,f]azepine-5-carboxamide) and oxcarbazepine (10,11-dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide) are widely used for the treatment of partial epilepsy. Recent work indicates that these drugs, in addition to targeting voltage-gated Na
+ channels, can modulate ligand-gated channels. These compounds appear to be particularly effective for treatment of nocturnal frontal lobe epilepsy, which can be caused by mutant neuronal nicotinic receptors. We compared the effects of carbamazepine and oxcarbazepine on heteromeric nicotinic receptors to better understand the underlying mechanism of the effect of these drugs in epileptic patients. Receptors were expressed in cell lines and studied by patch-clamp methods at -60mV. For α2β4 receptors activated with 100μM nicotine, IC
50 for carbamazepine was 49μM. Receptors in which α2 was substituted with α2-I279N, linked to autosomal dominant nocturnal frontal lobe epilepsy, had an IC
50 of 21μM. For oxcarbazepine, the IC
50 was larger than 500μM for wild-type receptors and approximately 100μM for mutant receptors. A similar inhibition was observed in the presence of 10μM nicotine, indicating a non-competitive mechanism. The monohydroxy derivative (MHD) of oxcarbazepine, clinically the most relevant compound, was tested on both α2β4 and α4β2 receptors, to obtain a broader view of its possible physiological effects. At the typical concentration present in blood (100μM), MHD produced an approximate 40% channel block on α4β2, but no significant effect on α2β4 receptors. Oxcarbazepine and MHD retarded the channel deactivation, suggesting that these compounds produce open channel block. These results may explain the particular efficacy of these drugs in nocturnal frontal lobe epilepsy.
AB - Carbamazepine (5H-dibenz[b,f]azepine-5-carboxamide) and oxcarbazepine (10,11-dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide) are widely used for the treatment of partial epilepsy. Recent work indicates that these drugs, in addition to targeting voltage-gated Na
+ channels, can modulate ligand-gated channels. These compounds appear to be particularly effective for treatment of nocturnal frontal lobe epilepsy, which can be caused by mutant neuronal nicotinic receptors. We compared the effects of carbamazepine and oxcarbazepine on heteromeric nicotinic receptors to better understand the underlying mechanism of the effect of these drugs in epileptic patients. Receptors were expressed in cell lines and studied by patch-clamp methods at -60mV. For α2β4 receptors activated with 100μM nicotine, IC
50 for carbamazepine was 49μM. Receptors in which α2 was substituted with α2-I279N, linked to autosomal dominant nocturnal frontal lobe epilepsy, had an IC
50 of 21μM. For oxcarbazepine, the IC
50 was larger than 500μM for wild-type receptors and approximately 100μM for mutant receptors. A similar inhibition was observed in the presence of 10μM nicotine, indicating a non-competitive mechanism. The monohydroxy derivative (MHD) of oxcarbazepine, clinically the most relevant compound, was tested on both α2β4 and α4β2 receptors, to obtain a broader view of its possible physiological effects. At the typical concentration present in blood (100μM), MHD produced an approximate 40% channel block on α4β2, but no significant effect on α2β4 receptors. Oxcarbazepine and MHD retarded the channel deactivation, suggesting that these compounds produce open channel block. These results may explain the particular efficacy of these drugs in nocturnal frontal lobe epilepsy.
KW - α2β4
KW - α4β2
KW - ADNFLE
KW - GP 47779
KW - I279N
KW - MHD
UR - http://www.scopus.com/inward/record.url?scp=77955086763&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955086763&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2010.05.063
DO - 10.1016/j.ejphar.2010.05.063
M3 - Article
C2 - 20561518
AN - SCOPUS:77955086763
VL - 643
SP - 13
EP - 20
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
SN - 0014-2999
IS - 1
ER -